Biopharma’s Sickly September

Most funds posted sharp losses, even as the indices were held their own.

Stephen Taub October 20, 2026

September was a rough month for prominent biopharma and life sciences hedge funds.Many lost money, some by double-digit percentage rates. As a result, quite a few funds are up only by single-digit rates or are in the red for the year after having outperformed the

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

4.30.02 build:2026-10-16 Login